Wegovy 7.2 mg: What the Higher-Dose Trial Found

A higher maximum is not an automatic next step

I would not assume that the highest familiar dose is the only dose now available. There is an approved 7.2 mg version of the same injection now², and the label says that after at least four weeks at 2.4 mg, if more weight reduction is clinically indicated, the dose can go up to a maximum of 7.2 mg once weekly¹.

I read the prescribing information to compare the trial results and adverse effects. A higher maximum is an option for an appropriate adult, not an instruction to increase a prescription.

What it buys

In a 72-week trial of adults with obesity, mean weight change was −3.9% on placebo, −15.5% on 2.4 mg, and −18.8% on 7.2 mg¹.

Tripling the dose moved the average by 3.3 percentage points — the label puts the difference from 2.4 mg at −3.3, with a confidence interval of −4.9 to −1.6¹. Three points. That is what triple buys on average.

The bottom row of that top section is the better argument for it. The share of people losing at least a fifth of their body weight went from about a third to nearly half. If you are someone for whom 2.4 mg produced a real but not-enough result, that is not nothing, and it is the honest case for asking.

What it charges you

I expected the cost to be nausea. Nausea barely moved — 35% to 39%.

The larger change was in altered skin sensation. Dysesthesia: 6% at 2.4 mg, 22% at 7.2 mg, less than 1% on placebo¹.

The label groups it with related events of altered skin sensation — pins and needles, skin that hurts, skin that feels oversensitive, a burning feeling on the skin — and states plainly that the incidence increased with increasing dose and with drug levels in the blood¹. More than one in five. That is not a footnote-level side effect.

This is the part I would discuss before considering the higher dose. Of 288 people who got it on the higher dose: 2% stopped the drug permanently, 8% paused, and 23% cut their dose. Most of the people who did something about it recovered, and the events resolved faster when something was done. But 18% had not reported recovering by the end of the trial — and the label notes that in most of those, the dose had been left unchanged¹.

And of the people who recovered and then went back up to 7.2 mg — 38 of them — 17, or 45%, had it come back¹.

It charges your wallet too: self-pay, the 7.2 mg dose costs more than the lower ones. I keep current numbers in my price breakdown.

The one I am still thinking about

There is a paragraph in the immunogenicity section that I have not seen anyone mention.

Over the 72 weeks, 15.4% of people on 7.2 mg developed antibodies to semaglutide, against 11.2% on 2.4 mg. Some of those antibodies cross-reacted with native GLP-1 — the hormone your own body makes. That was 36 of the 1,311 people on the higher dose, about 2.7%, against 3 of 304 on 2.4 mg, about 1.0%¹.

The label's own next sentence is the honest one: the clinical consequences of antibodies that cross-react with native GLP-1 are unknown¹. It also says no clinically significant effect on how the drug behaves in the body was seen, and that there is not enough evidence to characterize the effects on safety or effectiveness.

So it is not a warning. It is a blank space, and it is a slightly bigger blank space at the higher dose. I would want to know that before I tripled anything.

What I would ask, if I ask

• "Am I actually stalled, or am I impatient?" Hitting a plateau and a dose that never produced the expected benefit can raise different questions. I would ask the clinician to assess the pattern before considering a dose change.
• "What do we do if my skin starts feeling strange?" Given that 18% of participants who experienced dysesthesia did not report recovery during the trial, I would want that plan agreed in advance rather than improvised.
• "Is three points worth it for me?" For some people it plainly is. I would rather answer that on purpose than drift upward by default.

I would include hair-loss questions in the discussion if relevant, since the reported rate was higher at 7.2 mg. I would ask what benefit matters for my health, what monitoring is planned and what would prompt reassessment. I would not change a dose on my own.